Hair repigmentation associated with the use of lenalidomide: Graying may not be an irreversible process!

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 2, 2013, Pages 165-169

  Dasanu, Constantin A ^a   Mitsis, Demytra ^b   Alexandrescu, Doru T ^c  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

graying; hair follicle; Hair repigmentation; lenalidomide; melanocytes

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; CREATININE; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN M; INTERLEUKIN 1; INTERLEUKIN 6; LENALIDOMIDE; M PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE LESION; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CANCER THERAPY; CASE REPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; COMPRESSION FRACTURE; CREATININE BLOOD LEVEL; CYTOGENETICS; DRUG USE; FLOW CYTOMETRY; FOLLICULAR MELANOGENESIS; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAIR FOLLICLE; HAIR REPIGMENTATION; HEMATOPOIESIS; HUMAN; HYPERCALCEMIA; ILIAC BONE; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY FUNCTION; LOW BACK PAIN; LUMBOSACRAL SPINE; MALE; MELANOCYTE; MELANOGENESIS; MULTIPLE MYELOMA; NORMOCHROMIC NORMOCYTIC ANEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PIGMENT DISORDER; PLASMA CELL; PLASMACYTOSIS; PRIORITY JOURNAL; SPINAL PAIN; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE;

GRAYING; HAIR FOLLICLE; HAIR REPIGMENTATION; LENALIDOMIDE; MELANOCYTES;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CELL DIFFERENTIATION; CELL MOVEMENT; CYTOKINES; HAIR COLOR; HAIR FOLLICLE; HUMANS; MALE; MELANOCYTES; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84879289441     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212442561     Document Type: Article

References (28)

1. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 ; 106: 4050-4053
2. Hall VC, El-Azhary RA, Bouwhuis A, et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol. 2003 ; 48: 548-552
3. Sviggum HP, Davis MDP, Rajkumar SV, et al. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol. 2006 ; 142: 1298-1302
4. Persona EP, Mesa MG, Sanchez PJG, et al. Lenalidomide treatment for patients with multiple myeloma: Diagnosis and management of most frequent adverse events. Adv Ther. 2011 ; 28 (Suppl 1). 11-16
5. Galimont-Collen AFS, Vos LE, Lavrijsen APM, et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007 ; 43: 845-851
6. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev. 2006 ; 6: 803-813
7. Mak KK, Chan SY. Epidermal growth factor as a bioplogic switch in hair growth cycle. J Biol Chem. 2003 ; 278: 26120-26126
8. Santmyire-Rosenberger BR, Albert M. Acquired trichomegaly with topiramate. J Am Acad Dermatol. 2005 ; 53: 262-263
9. Saif MW, Gnanaraj J. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Cutan Ocul Toxicol. 2010 ; 29: 62-66
10. Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Derm Online J. 2009 ; 15: 4-4
11. Cohen PR, Escudier SM, Kurzrock R. Cetuximab-associated elongation of the eyelashes: Case report and review of eyelash trichomegaly secondary to epidermal growth factor inhibitors. Am J Clin Dermatol. 2011 ; 12: 63-67
12. Pascual JC, Banuls J, Belinchon I, et al. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol. 2004 ; 151: 1111-1112
13. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999 ; 341: 491-497
14. Slominski A, Paus R. Melanogenesis is coupled to murine anagen: Toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J Invest Dermatol. 1993 ; 101: 90S - 97S
15. Sugiyama S. Mode of redifferentiation and melanogenesis of melanocytes in mouse hair follicles. An ultrastructural and cytochemical study. J Ultrastruct Res. 1979 ; 67: 40-54
16. Lindner G, Botchkarev VA, Botchkareva NV, et al. Analysis of apoptosis during hair follicle regression (catagen). Am J Pathol. 1997 ; 151: 1601-1617
17. Tobin DJ, Hagen E, Botchkarev VA, et al. Do hair bulb melanocytes undergo apoptosis during hair follicle regression (catagen)?. J Invest Dermatol. 1998 ; 111: 941-947
18. Hearing VJ. Biochemical control of melanogenesis and melanosomal organization. J Investig Dermatol Symp Proc. 1999 ; 4: 24-28
19. Slominski A, Wortsman J, Luger T, et al. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000 ; 80: 979-1020
20. Slominski A, Paus R. Towards defining receptors for l-tyrosine and l-dopa. Mol Cell Endocrinol. 1994 ; 99: C7 - C11
21. Slominski A, Tobin DJ, Shibahara S, et al. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004 ; 84: 1122-1155
22. De Sanctis JB, Mijares M, Suárez A, et al. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov. 2010 ; 4: 144-148
23. Locker D, Superstine E, Sulman FG. The mechanism of the push and pull principle. 8. Endocrine effects of thalidomide and its analogues. Arch Int Pharmacodyn Ther. 1971 ; 194: 39-55
24. Brode E. Experimental studies with cyclic imides. I. Modification of hypophyseal-adrenal axis by thalidomide. Arzneimittelforschung. 1968 ; 18: 661-665
25. Redondo P, Guzman M, Marquina M, et al. Repigmentation of gray hair after thyroid hormone treatment. J Actas Dermosifiliogr. 2007 ; 98: 603-610
26. Faivre A, Delbaldo C, Vera K, et al. SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006 ; 24: 25-35
27. Alexandrescu DT, Dasanu CA, Farzanmehr H, et al. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J. 2008 ; 14: 7-7
28. Etienne G, Cony-Makhoul P and Mahon FX. Imatinib mesylate and gray hair. N Engl J Med 2002; 347:446.